What is Mangoceuticals, Inc. Common Stock?
engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States.
MGRX · Verdict
Moderate reward · high risk
MGRX has limited near-term tailwinds — volatility and balance sheet weigh on the model output.
Based on 88% data coverage
MGRX · Verdict
Weak vs peers
Current ratio 0.05
-790% free-cash-flow margin
-1414% net margin · -136% ROE
Earnings +689.4% CAGR
Model-based scoring. For information only — not financial advice.
engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 8.14M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.